Explore more publications!
Technology, Science, & Me!
Got News to Share?

Technology, Science, & Me!: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Technology, Science, & Me!.

November 2025

Mo Tu We Th Fr Sa Su
1 2
3 4 5 6 7 8 9
10 11 12 13 14 15 16
17 18 19 20 21 22 23
24 25 26 27 28 29 30

December 2025

Mo Tu We Th Fr Sa Su
1 2 3 4 5 6 7
8 9 10 11 12 13 14
15 16 17 18 19 20 21
22 23 24 25 26 27 28
29 30 31

January 2026

Mo Tu We Th Fr Sa Su
1 2 3 4
5 6 7 8 9 10 11
12 13 14 15 16 17 18
19 20 21 22 23 24 25
26 27 28 29 30 31

Press releases published on December 7, 2025

GoHighLevel SaaS Mode: New Guide Uncovers the Most Profitable Agency Model of 2026
December 7, 2025

GoHighLevel SaaS Mode: New Guide Uncovers the Most Profitable Agency Model of 2026

Indeterminate EIN Presswire
Same Day Garage Door, LLC Introduces Garage Door Replacement Program to Support Lima, OH Homes During Peak Winter Season
December 7, 2025

Same Day Garage Door, LLC Introduces Garage Door Replacement Program to Support Lima, OH Homes During Peak Winter Season

Indeterminate EIN Presswire
Leading Edge Network Announces 30 New Shows Launching January 2026 on DX Virtual TV
December 7, 2025

Leading Edge Network Announces 30 New Shows Launching January 2026 on DX Virtual TV

Indeterminate EIN Presswire
Smart Building Market Poised to Surpass $247.17 Billion by 2032 | Growing at 12.3% CAGR
December 7, 2025

Smart Building Market Poised to Surpass $247.17 Billion by 2032 | Growing at 12.3% CAGR

Indeterminate EIN Presswire
Inferenz and Caregence Announce Strategic Merger to Redefine AI Innovation in Healthcare
December 7, 2025

Inferenz and Caregence Announce Strategic Merger to Redefine AI Innovation in Healthcare

Indeterminate EIN Presswire
At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis
December 7, 2025

At ASH 2025 Oral Presentation, Immix Biopharma Reports Positive Phase 2 NXC-201 Results, Advancing Toward BLA Submission as a Potentially First- and Best-in-Class Therapy for relapsed/refractory AL Amyloidosis

Indeterminate GlobeNewswire
ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025
December 7, 2025

ImCheck Reports Durable Responses and Early Overall Survival Signal with ICT01 in First-line AML at ASH 2025

Indeterminate GlobeNewswire
Les forages recoupent une large zone minéralisée dans un nouveau secteur bien en dehors des ressources
December 7, 2025

Les forages recoupent une large zone minéralisée dans un nouveau secteur bien en dehors des ressources

Indeterminate GlobeNewswire
Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition
December 7, 2025

Lyell Immunopharma Presents New Clinical Data from Ongoing Trial of Ronde-Cel Showing High Rates of Durable Complete Responses in Patients with Large B-cell Lymphoma at the 67th ASH Annual Meeting and Exposition

Indeterminate GlobeNewswire
Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment
December 7, 2025

Lynozyfic™ (linvoseltamab) Monotherapy in Newly Diagnosed Multiple Myeloma (NDMM) Shows Impressive Responses, Supporting Rationale as a Potential Foundation in Frontline Treatment

Indeterminate GlobeNewswire
Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET
December 7, 2025

Dyne Therapeutics to Host Investor Conference Call and Webcast to Review Topline Results from Registrational Expansion Cohort (REC) of DELIVER Clinical Trial of Z-Rostudirsen (DYNE-251) in Duchenne Muscular Dystrophy; Tomorrow, December 8 at 8:00 a.m. ET

Indeterminate GlobeNewswire
Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease
December 7, 2025

Prime Medicine Announces The New England Journal of Medicine Publication of PM359 Clinical Data for the Treatment of Chronic Granulomatous Disease

Indeterminate GlobeNewswire
ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting
December 7, 2025

ALX Oncology Announces Positive Results from Ongoing Investigator-Sponsored Phase 2 Trial Evaluating Evorpacept in Combination with Standard-of-Care Treatment in Patients with Indolent B-cell Non-Hodgkin Lymphoma, at ASH Annual Meeting

Indeterminate GlobeNewswire
Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting
December 7, 2025

Molecular Partners Presents Updated Data from Ongoing Phase 1/2a Trial of MP0533 in AML at ASH Annual Meeting

Indeterminate GlobeNewswire
Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA
December 7, 2025

Pixalate’s Q3 2025 Report Uncovers 1,248 APAC-Registered Mobile Apps Across Apple App & Google Play Stores Violating COPPA, Impacting 117 Million Child-App Users in USA

Indeterminate GlobeNewswire
SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire
December 7, 2025

SALI Showcases Global Ambition with Times Square Billboard Campaign, Marking a New Milestone in Its Journey Toward a Global Power Tool Accessories Empire

Indeterminate GlobeNewswire

Share us

on your social networks:
Facebook Facebook LinkedIn LinkedIn
AGPs

Get the latest news on this topic.

SIGN UP FOR FREE TODAY

No Thanks

By signing to this email alert, you
agree to our Terms & Conditions